| __timestamp | Ligand Pharmaceuticals Incorporated | Veracyte, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 22570000 | 40786000 |
| Thursday, January 1, 2015 | 24378000 | 47876000 |
| Friday, January 1, 2016 | 26621000 | 52035000 |
| Sunday, January 1, 2017 | 28653000 | 55348000 |
| Monday, January 1, 2018 | 37734000 | 65276000 |
| Tuesday, January 1, 2019 | 41884000 | 82720000 |
| Wednesday, January 1, 2020 | 64435000 | 89118000 |
| Friday, January 1, 2021 | 57483000 | 181193000 |
| Saturday, January 1, 2022 | 70062000 | 174078000 |
| Sunday, January 1, 2023 | 52790000 | 184232000 |
Cracking the code
In the dynamic world of biotechnology, understanding financial trends is crucial. Over the past decade, Veracyte, Inc. and Ligand Pharmaceuticals Incorporated have showcased distinct trajectories in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Veracyte's SG&A expenses surged by approximately 350%, reflecting its aggressive growth strategy and market expansion. In contrast, Ligand Pharmaceuticals exhibited a more moderate increase of around 130%, indicating a steady, controlled approach to its operational expenditures.
By 2023, Veracyte's SG&A expenses were nearly 3.5 times higher than in 2014, peaking at over $184 million. Meanwhile, Ligand's expenses reached their zenith in 2022, with a 210% increase from 2014. These patterns highlight the contrasting business models and strategic priorities of these two industry players, offering valuable insights for investors and stakeholders.
SG&A Efficiency Analysis: Comparing Vertex Pharmaceuticals Incorporated and Ligand Pharmaceuticals Incorporated
SG&A Efficiency Analysis: Comparing Incyte Corporation and Ligand Pharmaceuticals Incorporated
SG&A Efficiency Analysis: Comparing Viatris Inc. and Ligand Pharmaceuticals Incorporated
Breaking Down SG&A Expenses: Dr. Reddy's Laboratories Limited vs Veracyte, Inc.
Breaking Down SG&A Expenses: Catalent, Inc. vs Veracyte, Inc.
Comparing SG&A Expenses: CRISPR Therapeutics AG vs Veracyte, Inc. Trends and Insights
Comparing SG&A Expenses: Veracyte, Inc. vs Dynavax Technologies Corporation Trends and Insights
Who Optimizes SG&A Costs Better? Veracyte, Inc. or Galapagos NV
Veracyte, Inc. or Celldex Therapeutics, Inc.: Who Manages SG&A Costs Better?
Veracyte, Inc. or MiMedx Group, Inc.: Who Manages SG&A Costs Better?
Protagonist Therapeutics, Inc. and Ligand Pharmaceuticals Incorporated: SG&A Spending Patterns Compared
Breaking Down SG&A Expenses: Ligand Pharmaceuticals Incorporated vs MannKind Corporation